NEW YORK (GenomeWeb News) – CombiMatrix today priced its public offering of 12,000 units of preferred of Series D convertible preferred stock and warrants at a price of $1,000 per unit.

Gross proceeds from the offering are $12 million, with net proceeds anticipated to be $10.8 million. The array-based molecular diagnostics developer said that it expects to close the offering on or around Dec. 20.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.

Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.

In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.

The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.